Down-regulating HIF-1α by lentivirus-mediated shRNA for therapy of triple negative breast cancer

References

• Ban KA, Godellas CV. Epidemiology of Breast Cancer. Surg Oncol Clin N Am 2014; 23:409–22; PMID:24882341; http://dx.doi.org/10.1016/j.soc.2014.03.011
   PubMed Web of Science ®Google Scholar
• Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin 2014; 64:9–29; PMID:24399786; http://dx.doi.org/10.3322/caac.21208
   PubMed Web of Science ®Google Scholar
• DeSantis C, Ma J, Bryan L, Jemal A. Breast cancer statistics, 2013. CA Cancer J Clin 2014; 64:52–62; PMID:24114568; http://dx.doi.org/10.3322/caac.21203
   PubMed Web of Science ®Google Scholar
• de Boer M, van Dijck JA, Bult P, Borm GF, Tjan-Heijnen VC. Breast cancer prognosis and occult lymph node metastases, isolated tumor cells, and micrometastases. J Natl Cancer Inst 2010; 102:410–25; PMID:20190185; http://dx.doi.org/10.1093/jnci/djq008
   PubMed Web of Science ®Google Scholar
• Bernard-Marty C, Cardoso F, Piccart MJ. Facts and controversies in systemic treatment of metastatic breast cancer. Oncologist 2004; 9:617–32; PMID:15561806; http://dx.doi.org/10.1634/theoncologist.9-6-617
   PubMed Web of Science ®Google Scholar
• de Ruijter TC, Veeck J, de Hoon JP, van Engeland M, Tjan-Heijnen VC. Characteristics of triple-negative breast cancer. J Cancer Res Clin Oncol 2011; 137:183–92; PMID:21069385; http://dx.doi.org/10.1007/s00432-010-0957-x
   PubMed Web of Science ®Google Scholar
• Yadav BS, Sharma SC, Chanana P, Jhamb S. Systemic treatment strategies for triple-negative breast cancer. World J Clin Oncol 2014; 5:125–33; PMID:24829859; http://dx.doi.org/10.5306/wjco.v5.i2.125
   PubMedGoogle Scholar
• Barsoum IB, Koti M, Siemens DR, Graham CH. Mechanisms of hypoxia-mediated immune escape in cancer. Cancer Res 2014; (24):7185-90.
   Web of Science ®Google Scholar
• Pettersen EO, Ebbesen P, Gieling RG, Williams KJ, Dubois L, Lambin P, Ward C, Meehan J, Kunkler IH, Langdon SP, et al. Targeting tumour hypoxia to prevent cancer metastasis. From biology, biosensing and technology to drug development: the METOXIA consortium. J Enzyme Inhib Med Chem 2014; 27:1–33; http://dx.doi.org/10.3109/14756366.2014.966704
   Web of Science ®Google Scholar
• Wang GL, Semenza GL. Purification and characterization of hypoxiainducible factor-1. J Biol Chem 1995;270:1230–7; PMID:7836384; http://dx.doi.org/10.1074/jbc.270.3.1230
   PubMed Web of Science ®Google Scholar
• Salceda S, Beck I, Caro J. Absolute requirement of aryl hydrocarbon receptor nuclear translocator protein for gene activation by hypoxia. Arch Biochem Biophys 1996; 334:389–94; PMID:8900415; http://dx.doi.org/10.1006/abbi.1996.0469
   PubMed Web of Science ®Google Scholar
• Liu L, Marti GP, Wei X, Zhang X, Zhang H, Liu YV, Nastai M, Semenza GL, Harmon JW. Age-dependent impairment of HIF-1alpha expression in diabetic mice: Correction with electroporation-facilitated gene therapy increases wound healing, angiogenesis, and circulating angiogenic cells. J Cell Physiol 2008; 217:319–27; PMID:18506785; http://dx.doi.org/10.1002/jcp.21503
   PubMed Web of Science ®Google Scholar
• Shibuya M. VEGF-VEGFR Signals in Health and Disease. Biomol Ther (Seoul). 2014; 22:1–9; PMID:24596615; http://dx.doi.org/10.4062/biomolther.2013.113
   PubMed Web of Science ®Google Scholar
• Semenza GL. Signal transduction to hypoxia-inducible factor 1. Biochem Pharmacol 2002; 64:993–8; PMID:12213597; http://dx.doi.org/10.1016/S0006-2952(02)01168-1
   PubMed Web of Science ®Google Scholar
• Agani F, Jiang BH. Oxygen-independent regulation of HIF-1: novel involvement of PI3K/AKT/mTOR pathway in cancer. Curr Cancer Drug Targets. 2013;13:245–251; PMID:23297826; http://dx.doi.org/10.2174/1568009611313030003
   PubMed Web of Science ®Google Scholar
• Subtil FS, Wilhelm J, Bill V, Westholt N, Rudolph S, Fischer J, Scheel S, Seay U, Fournier C, Taucher-Scholz G, et al. Carbon ion radiotherapy of human lung cancer attenuates HIF-1 signaling and acts with considerably enhanced therapeutic efficiency. FASEB J. 2014;28:1412–21; PMID:24347608; http://dx.doi.org/10.1096/fj.13-242230
   PubMed Web of Science ®Google Scholar
• Warfel NA, El-Deiry WS. HIF-1 signaling in drug resistance to chemotherapy. Curr Med Chem. 2014;21:3021–8; PMID:24735366; http://dx.doi.org/10.2174/0929867321666140414101056
   PubMed Web of Science ®Google Scholar
• Miura Y, Ohnami S, Yoshida K, Ohashi M, Nakano M, Fukuhara M, Yanagi K, Matsushita A, Uchida E, Asaka M, et al. Intraperitoneal injection of adenovirus expressing antisense K-ras RNA suppresses peritoneal dissemination of hamster syngeneic pancreatic cancer without systemic toxicity. Cancer Lett 2005; 218:53–62; PMID:15639340; http://dx.doi.org/10.1016/j.canlet.2004.08.015
   PubMed Web of Science ®Google Scholar
• Trujillo MA, Oneal MJ, Davydova J, Bergert E, Yamamoto M, Morris JC 3rd. Construction of an MUC-1 promoter driven, conditionally replicating adenovirus that expresses the sodium iodide symporter for gene therapy of breast cancer. Breast Cancer Res 2009; 11:R53; PMID:19635153; http://dx.doi.org/10.1186/bcr2342
   PubMed Web of Science ®Google Scholar
• Young LS, Searle PF, Onion D, Mautner V. Viral gene therapy strategies: from basic science to clinical application. J Pathol 2006; 208:299–318; PMID:16362990; http://dx.doi.org/10.1002/path.1896
   PubMed Web of Science ®Google Scholar
• Monti E, Gariboldi MB. HIF-1 as a target for cancer chemotherapy, chemosensitization and chemoprevention. Curr Mol Pharmacol. 2011; 4:62–77; PMID:20958262; http://dx.doi.org/10.2174/1874467211104010062
   PubMedGoogle Scholar
• Meijer TW, Kaanders JH, Span PN, Bussink J. Targeting hypoxia, HIF-1, and tumor glucose metabolism to improve radiotherapy efficacy. Clin Cancer Res. 2012;18:5585–94; PMID:23071360; http://dx.doi.org/10.1158/1078-0432.CCR-12-0858
   PubMed Web of Science ®Google Scholar
• Wilczynski J, Duechler M, Czyz M. Targeting NF-κB and HIF-1 pathways for the treatment of cancer: part II. Arch Immunol Ther Exp (Warsz). 2011;59:301–7; PMID:21625847
   PubMedGoogle Scholar
• Zhu X, LI Q, Li S, Chen B, Zou H. HIF-1α decoy oligodeoxynucleotides inhibit HIF-1α signaling and breast cancer proliferation. Int J Oncol 2015; 46: 215–22; PMID:25334080
   PubMed Web of Science ®Google Scholar
• Newman LA, Reis-Filho JS, Morrow M, Carey LA, King TA. The 2014 Society of Surgical Oncology Susan G. Komen for the Cure Symposium: Triple-Negative Breast Cancer. Ann Surg Oncol. 2015; 22(3):874-82.
   Google Scholar
• Foulkes WD, Smith IE, Reis JS. Triple-Negative Breast Cancer. N Engl J Med 2010; 363: 1938–48; PMID:21067385; http://dx.doi.org/10.1056/NEJMra1001389
   PubMed Web of Science ®Google Scholar
• Cleator S, Heller W, Coombes RC. Triple-negative breast cancer: therapeutic options. Lancet Oncol 2007; 8: 235–44; PMID:17329194; http://dx.doi.org/10.1016/S1470-2045(07)70074-8
   PubMed Web of Science ®Google Scholar
• Sohn J, Liu S, Parinyanitikul N, Lee J, Hortobagyi GN, Mills GB, Ueno NT, Gonzalez-Angulo AM. cMET Activation and EGFR-Directed Therapy Resistance in Triple-Negative Breast Cancer. J cancer 2014; 5: 745–53; PMID:25368674; http://dx.doi.org/10.7150/jca.9696
   PubMed Web of Science ®Google Scholar
• Al-Hajj M, Wicha MS, Benito-Hernandez A, Morrison SJ, Clarke MF: Prospective identification of tumorigenic breast cancer cells. Proc Natl Acad Sci USA 2003; 100:3983–8; PMID:12629218; http://dx.doi.org/10.1073/pnas.0530291100
   PubMed Web of Science ®Google Scholar
• Li S, Li Q. Cancer stem cells and tumor metastasis. Int J Oncol 2014; 44:1806–12; PMID:24691919
   PubMed Web of Science ®Google Scholar
• Li S, Li Q. Cancer stem cells, lymphangiogenesis, and lymphatic metastasis. Cancer Lett 2015; 357(2):438-47 pii: S0304-3835(14)00756-3. doi: 10.1016/j.canlet.2014.12.013. [Epub ahead of print].
   Google Scholar
• Semenza GL. HIF-1 and human disease: one highly involved factor. Genes Dev 2000; 14:1983–91; PMID:10950862
   PubMed Web of Science ®Google Scholar
• Bos R, van der Groep P, Greijer AE, Shvarts A, Meijer S, Pinedo HM, Semenza GL, van Diest PJ, van der Wall E. Levels of hypoxia-inducible factor-1alpha independently predict prognosis in patients with lymph node negative breast carcinoma. Cancer 2003; 97:1573–81; PMID:12627523; http://dx.doi.org/10.1002/cncr.11246
   PubMed Web of Science ®Google Scholar
• Martin SK, Diamond P, Gronthos S, Peet DJ, Zannettino AC. The emerging role of hypoxia, HIF-1 and HIF-2 in multiple myeloma. Leukemia 2011; 25:1533–42; PMID:21637285; http://dx.doi.org/10.1038/leu.2011.122
   PubMed Web of Science ®Google Scholar
• Kamlah F, Eul BG, Li S, Lang N, Marsh LM, Seeger W, Grimminger F, Rose F, Hänze J. Intravenous injection of siRNA directed against hypoxia-inducible factors prolongs survival in a Lewis lung carcinoma cancer model. Cancer Gene Ther 2009; 16:195–205; PMID:18818708
   PubMed Web of Science ®Google Scholar
• Greijer AE, van der Wall E. The role of hypoxia inducible factor 1 (HIF-1) in hypoxia induced apoptosis. J Clin Pathol 2004; 57:1009–14; PMID:15452150; http://dx.doi.org/10.1136/jcp.2003.015032
   PubMed Web of Science ®Google Scholar
• Akakura N, Kobayashi M, Horiuchi I, Suzuki A, Wang J, Chen J, Niizeki H, Kawamura Ki, Hosokawa M, Asaka M. Constitutive expression of hypoxia-inducible factor-1 α renders pancreatic cancer cells resistant to apoptosis induced by hypoxia and nutrient deprivation. Cancer Res 2001; 61:6548–54; PMID:11522653
   PubMed Web of Science ®Google Scholar
• Chen C, Yu Z. siRNA Targeting HIF-1α Induces Apoptosis of Pancreatic Cancer Cells through NF-κB-independent and –dependent Pathways under Hypoxic Conditions. Anticancer Res 2009; 29: 1367–72; PMID:19414389
   PubMed Web of Science ®Google Scholar
• Shimizu S, Eguchi Y, Kosaka H, Kamiike W, Matsuda H, Tsujimoto Y. Prevention of hypoxia-induced cell death by Bcl−2 and Bcl−xL. Nature 1995; 374:811–3; PMID:7723826; http://dx.doi.org/10.1038/374811a0
   PubMed Web of Science ®Google Scholar
• Goda N, Ryan HE, Khadivi B, McNulty W, Rickert RC, Johnson RS. Hypoxia-inducible factor 1 α is essential for cell cycle arrest during hypoxia. Mol Cell Biol 2003; 23:359–69; PMID:12482987; http://dx.doi.org/10.1128/MCB.23.1.359-369.2003
   PubMed Web of Science ®Google Scholar
• Wu WD, Hu ZM, Shang MJ, Zhao DJ, Zhang CW, Hong DF, Huang DS. Cordycepin down-regulates multiple drug resistant (MDR)/HIF-1α through regulating AMPK/mTORC1 signaling in GBC-SD gallbladder cancer cells. Int J Mol Sci 2014;15:12778–90; PMID:25046749; http://dx.doi.org/10.3390/ijms150712778
   PubMed Web of Science ®Google Scholar
• Stavrovskaya AA, Stromskaya TP. Transport proteins of the ABC family and multidrug resistance of tumor cells. Biochemistry (Mosc) 2008; 73:592–604; PMID:18605983; http://dx.doi.org/10.1134/S0006297908050118
   PubMed Web of Science ®Google Scholar
• Chen L, Feng P, Li S, Long D, Cheng J, Lu Y, Zhou D. Effect of hypoxiainducible factor-1alpha silencing on the sensitivity of human brain glioma cells to doxorubicin and etoposide. Neurochem Res 2009; 34:984–90; PMID:18937067; http://dx.doi.org/10.1007/s11064-008-9864-9
   PubMed Web of Science ®Google Scholar
• Comerford KM, Wallace TJ, Karhausen J, Louis NA, Montalto MC, Colgan SP. Hypoxia-inducible factor-1-dependent regulation of the multidrug resistance (MDR1) gene. Cancer Res 2002; 62:3387–94; PMID:12067980
   PubMed Web of Science ®Google Scholar
• Liao H, Wang G, Gu L, Huang S, Chen X, Li Y, Cai S. HIF-1α siRNA and Cisplatin in Combination Suppress Tumor Growth in a Nude Mice Model of Esophageal Squamous Cell Carcinoma. Asian Pacific J Cancer Prev 2012; 13:473–7; http://dx.doi.org/10.7314/APJCP.2012.13.2.473
   PubMed Web of Science ®Google Scholar
• Rajagopalan S, Olin J, Deitcher S, Pieczek A, Laird J, Grossman PM, Goldman CK, McEllin K, Kelly R, Chronos N. Use of a constitutively active hypoxia-inducible factor-1alpha transgene as a therapeutic strategy in no-option critical limb ischemia patients: phase I dose-escalation experience. Circulation 2007;115:1234–43; PMID:17309918
   PubMed Web of Science ®Google Scholar